AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Catalent Pharma Solutions.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Catalent Pharma Solutions
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
14 Schoolhouse Road, Somerset, NJ 08873
Telephone
Telephone
+1 877-587-1835

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

The partnership aims to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies, being developed for the treatment of cancer.


Lead Product(s): AAV-based Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Siren Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Melt Pharmaceuticals will utilize Catalent’s proprietary Zydis® orally disintegrating tablet fast-dissolve technology with MELT-300 (midazolam), a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery.


Lead Product(s): Midazolam,Ketamine Hydrochloride

Therapeutic Area: Neurology Product Name: Melt-300

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Melt Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Mind Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.


Lead Product(s): Naloxone Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Rivive

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Harm Reduction Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmaceutics™ platform.


Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Grunenthal

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

PSI-GAD (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.


Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Incannex Healthcare

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the license agreement, Catalent and Ethicann will develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology including EPI-002 (cannabinoid) candidate to treat MS spasticity.


Lead Product(s): Cannabinoid

Therapeutic Area: Musculoskeletal Product Name: EPI-002

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Ethicann Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.


Lead Product(s): Etilevodopa

Therapeutic Area: Neurology Product Name: Inbrija

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Acorda Therapeutics

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Agreement January 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of essential components of dystrophin.


Lead Product(s): Delandistrogene Moxeparvovec

Therapeutic Area: Genetic Disease Product Name: SRP-9001

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Sarepta Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.


Lead Product(s): Antibody-drug Conjugate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Exelixis

Deal Size: Undisclosed Upfront Cash: $30.0 million

Deal Type: Licensing Agreement November 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY